Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Diagnosis
* Histologically confirmed stage II-III non-small cell lung cancer (NSCLC)
2. Treatment Plan
* Planned to receive concurrent platinum-based chemotherapy with radiotherapy (cCRT)
3. Demographics
* Age 18-80 years
4. Performance Status
* Karnofsky Performance Status (KPS) ≥70
5. Organ Function
* Renal function: Creatinine clearance ≥60 mL/min
* Hepatic function: Total bilirubin ≤1.5×ULN, AST/ALT ≤2.5×ULN
* Absolute neutrophil count ≥2.0×10⁹/L
* Platelets ≥100×10⁹/L
* Hemoglobin ≥10 g/dL
You may not be if
1. Active Malignancies
* Concurrent diagnosis of active malignancies (excluding: non-melanoma skin cancer, carcinoma in situ, or malignancies in complete remission for ≥5 years)
2. Infectious/Immunological Conditions
* Active systemic infection requiring intravenous antimicrobial therapy
* Uncontrolled autoimmune diseases (defined as requiring systemic immunosuppressants at doses \>10 mg/day prednisone equivalent within 30 days prior to screening)
3. Hypersensitivity Reactions
* Allergy to PEG-rhG-CSF or other biological products derived from genetically engineered Escherichia coli
4. Neuropsychiatric Impairments
* Severe psychiatric disorders (e.g., schizophrenia, major depressive disorder with suicidal ideation) requiring hospitalization within 6 months)
5. Prior Radiotherapy
* History of thoracic radiotherapy involving \>30% lung parenchyma or mean heart dose \>20 Gy
Clareo Health | Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC
